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Abstract 
There is an unmet need to understand the mechanisms underlying skeletal deterioration 
in diabetes mellitus (DM) and to develop therapeutic approaches to treat bone fragility 
in diabetic patients. We demonstrate herein that mice with type 1 DM induced by 
streptozotocin exhibited low bone mass, inferior mechanical and material properties, 
increased bone resorption, decreased bone formation, increased apoptosis of osteocytes, 
and increased expression of the osteocyte-derived bone formation inhibitor 
Sost/sclerostin. Further, short treatment of diabetic mice with parathyroid hormone 
related protein (PTHrP)-derived peptides corrected these changes to levels 
undistinguishable from non-diabetic mice. In addition, diabetic mice exhibited reduced 
bone formation in response to mechanical stimulation, which was corrected by 
treatment with the PTHrP peptides; and higher prevalence of apoptotic osteocytes, 
which was reduced by loading or by the PTHrP peptides alone, and reversed by a 
combination of loading and PTHrP peptide treatment. In vitro experiments 
demonstrated that the PTHrP peptides or mechanical stimulation by fluid flow activated 
the survival kinases ERKs and induced nuclear translocation of the canonical Wnt 
signaling mediator β-catenin; and prevented the increase in osteocytic cell apoptosis 
induced by high glucose. Thus, PTHrP-derived peptides crosstalk with mechanical 
signaling pathways to reverse skeletal deterioration induced by DM in mice. These 
findings suggest a crucial role of osteocytes in the harmful effects of diabetes on bone 
and raise the possibility of targeting these cells as a novel approach to treat skeletal 
deterioration in diabetes. Moreover, our study suggest the potential therapeutic efficacy 
of combined pharmacological and mechanical stimuli to promote bone accrual and 
maintenance in diabetic subjects. 
KEY WORDS: diabetes, osteocytes, Sost/sclerostin, PTHrP, osteocyte apoptosis 
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Introduction 
Diabetes mellitus (DM) is a highly prevalent disease with negative impact on the 
skeleton, which markedly increases fracture risk (1). In subjects with type 1 DM (T1D), 
bone mass is consistently decreased, whereas in those with type 2 DM bone mass is 
usually normal or even high; but in both cases there are concomitant alterations in bone 
structure and strength that compromise bone quality (2). Diabetic subjects show 
decreased bone formation and increased resorption due to complex and yet ill-defined 
mechanisms, including hyperglycemia and accumulation of advanced glycation end 
products, deficiency in insulin/insulin-like growth factor 1 secretion, and alterations in 
the parathyroid hormone (PTH)/Vitamin D axis. The morbidity and mortality associated 
with bone fractures are especially aggravated by alterations in fracture healing (3).  
 Earlier work demonstrated downregulation of PTH-related protein (PTHrP) and 
osteopenia in streptozotozin (STZ)-induced T1D in mice (4). PTHrP is a ubiquitous 
cytokine with important functions in bone development and metabolism. Administration 
of PTHrP-derived peptides that interact with the same receptor than PTH and PTHrP 
(PTH1R), or the PTH-unrelated peptide PTHrP(107-139), exert osteogenic effects in 
osteopenic mouse models (5). 
Mechanical stimulation, such as in physical exercise, is anabolic for the 
skeleton, while immobilization leads to bone loss. Accumulated evidence demonstrates 
that osteocytes are major cells responsible for bone adaptation to changes in mechanical 
force (6). Osteocytes are located into lacunae within the mineralized matrix, and connect 
among themselves and osteoblasts and osteoclasts on the bone surface through a 
network of dendritic processes, allowing osteocytes to act as orchestrators of bone 
remodeling (7). Mice with heterozygous Ins2Akita mutation, a spontaneous T1D model, 
show a reduction in osteocyte processes, increased spacing of lacunae, and deficient 
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bone formation in response to loading (8,9). The same investigators reported that MLO-
Y4 osteocytic cells exposed to high glucose showed impaired responses to mechanical 
stimulation in vitro. Further, we found increased osteocyte apoptosis in bone of STZ-
induced diabetic CD1 mice, effect that was counteracted by treatment with N- and C-
terminal PTHrP peptides for 2 weeks (10).  
A central role of the PTH1R expressed in osteocytes is supported by studies in 
transgenic mice expressing an activated PTH1R in these cells, which exhibit high bone 
remodeling and increased bone mass, recapitulating the actions of PTH on the 
skeleton(11). In contrast, mice lacking the PTH1R in mature osteoblasts/osteocytes show 
a deficient response to systemic PTH elevation (12); and mice lacking the PTH1R in 
osteocytes exhibit impaired response to mechanical stimulation (13). Further, 
PTHrP/PTH1R signaling is involved in fluid flow-induced survival of osteocytic cells in 
vitro (14).  
In the present study, we demonstrate that short treatment with two different 
PTHrP-derived peptides restored in part the loss of bone mass and strength by targeting 
both bone formation and bone resorption, and worked additively with mechanical 
loading to enhance periosteal bone formation and to promote osteocyte survival in 
diabetic mice in vivo. Further, the PTHrP peptides together with mechanical 
stimulation, activate survival signaling and prevent the pro-apoptotic effect of high 
glucose in osteocytic cells in vitro. These findings suggest the potential therapeutic 
efficacy of combined pharmacological and mechanical stimuli to promote bone accrual 
and maintenance in diabetic subjects. 
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Materials and Methods  
Animal model  
One hundred and thirty three 3-month old male C57BL/6 mice (Harlan, 
Indianapolis, IN) randomized by spinal BMD were used in the study (Figure 1A). Mice 
were grouped housed (5 mice/cage) and fed a standard rodent diet (Harlan/Teklad 
#7001), received water ad-libitum and exposed to a 12h light/dark cycle. T1D was 
induced by 5 daily injections of STZ (45mg/kg i.p. in 50 mM citrate buffer, pH 4.5) or 
buffer alone (controls), followed by glucose measurements after 18 days to confirm 
T1D (nonfasting blood glucose >250 mg/dL) (4). After 28 days to allow bone loss, 
diabetic mice were assigned to 3 groups, which received 3 daily s.c. injections of 
vehicle (50 mM KCl, pH 4.5), or 50 μg/kg PTHrP(1-37) or 7 μg/kg PTHrP(107-111) 
(Bachem, Bubendorf, Switzerland). Fifteen min after each injection, right ulna were 
loaded for 1 min, at 120 cycles/day at forces required to generate low, medium or high 
mechanical strains (see below). Mice were euthanized 15 days after the first loading 
bout; and bones were analyzed. Loading strains were determined in a previous 
experiment as previously published (15-17). Ten 3-month-old male C57BL/6 mice 
(Harlan, Barcelona, Spain) received 5 daily injections of buffer (controls) or STZ (T1D) 
and sacrified after 4 weeks. Right forearms were dissected to expose the ulnar 
diaphysis, and a miniature single element strain gauge (EA-015DJ-120; Vishay, Inc.) 
was bonded to the midshaft. Forearms were placed in a computer-controlled 
electromagnetic mechanical actuator (Bose, Eden Prairie, MN), and exposed to cyclic 
axial compression using a 2-Hz haversine waveform. The peak force was progressively 
increased with each cycle, and ranged from 1.2 to 2.4 N. During loading, conditioned 
voltage output from the strain gauge and output from the load cell were recorded; and 
voltage output converted to strain using previously described calibration procedures. 
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From these data the force:strain relation was derived for both groups, and low, medium, 
and high loads for in vivo mechanical loading were calculated so that 1,995; 2,250 and 
2,500 µstrain were generated for both genotypes. No significant difference in the 
strain/load ratio was found between control and T1D mice (947.7±118.6 and 
864.3±92.2 με/N, respectively). Protocols were approved by the Institutional Animal 
Care and Use Committee at Fundación Jiménez Díaz, Spain according to the European 
Union guidelines, and the Institutional Animal Care and Use Committee of Indiana 
University School of Medicine, USA. 
Bone turnover markers 
Osteocalcin (OCN) (Alpha Aesar-Johnson Matthey Co. Ward Hill, MA) and C-
telopeptide fragments of type I collagen (CTX) (RatLaps, Immunodiagnostic Systems 
Inc., Fountain Hills, AZ) were measured following manufacturer’s instructions (18,19). 
Bone mineral density (BMD) and microcomputerized tomography (μCT) analysis  
BMD was measured by dual energy X-ray absorptiometry using a PIXImus II 
densitometer (GE Medical Systems, Lunar Division, Madison, WI) and μCT analysis at 
6 µm-resolution was performed using a Scanco μCT 35 instrument (Scanco Medical, 
Brüttisellen, Switzerland) (18).  
Biomechanical testing 
Femoral 3-point bending was performed using a miniature bending apparatus 
(20). Mechanical properties were determined from the load deformation curves using 
standard definitions. Cross-sectional moment of inertia and anterior-posterior diameter 
determined by CT were used to calculate material level properties using standard 
equations. 
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Bone histology  
Mice were injected with calcein and alizarin red (30 and 50 mg/kg; Sigma), 7 
and 2 days before sacrifice, respectively (18). Bones were dissected, fixed in 10% 
buffered formalin, and embedded in methyl methacrylate. Thick, 100-μm cross-sections 
at the ulnae mid-diaphysis ground to 40 μm; and thin, 5 μm longitudinal sections from 
L1-L3 vertebrae, were prepared for dynamic and static histomorphometric analysis, 
respectively. Analysis was performed using OsteoMeasure (OsteoMetrics Inc., Decatur, 
GA). The terminology and units used are those recommended by the Histomorphometry 
Nomenclature Committee of the American Society for Bone and Mineral Research (21). 
Osteocyte apoptosis by TdT-mediated dUTP nick-end labeling (TUNEL; EMD 
Millipore, Billerica, MA) and sclerostin immunohistochemistry were performed on 
demineralized, paraffin embedded, consecutive 5 µm longitudinal sections of ulnae 
mid-diaphysis (19,22). Immunohistochemistry was performed using anti-mouse sclerostin 
antibody (R&D Systems, Minneapolis, MN), or non-immune IgG as negative control, 
followed by rabbit anti-goat horseradish peroxidase-coupled antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA). Color was developed with a diaminobenzidine 
substrate chromogen system (Dako Corp., Carpinteria, CA). In both cases, sections 
were counterstained with 2% methyl green, and observed under an Olympus BX51TRF 
microscope (Olympus America Inc., Center Valley, PA) at 400× magnification. The 
percentage of sclerostin-positive osteocytes was quantified in the medial region of the 
ulnae and analyzed using OsteoMeasure. Adipocyte area was quantified using the 
OsteoMeasure system (OsteoMetrics Inc., Decatur, GA) on the same ulnae sections 
stained for sclerostin and conterstained with 2% methyl green. Adipocytes within the 
marrow cavity were identified by morphology, and adipocyte area was corrected by 
bone marrow area. 
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RNA extraction and quantitative PCR (qPCR)  
Total RNA was extracted from mouse tibiae using TRIzol (Invitrogen, Grand 
Island, NY), and cDNA was synthesized using the Invitrogen Superscript First-strand 
Synthesis System for RT-PCR. Gene expression was quantified by qPCR performed as 
described(18), using sets of primers and probes designed using the Assay Design Center 
(Roche Applied Science, Indianapolis, IN) or commercially available carried out in an 
ABI PRISM 7500 system (Applied Biosystems, Foster City, CA). Results were 
calculated for each sample using the cycle threshold (Ct) value, and were normalized 
against ribosomal protein S2 (ChoB) as housekeeping gene.  
Cell culture 
Osteocytic MLO-Y4 cells were grown at 20,000 cells/cm2 on collagen-coated 
culture plates, as previously published (23,24). Twenty four hours later, fresh culture 
medium was added with or without 25 mM high D-glucose (or L-glucose as osmotic 
control) and cells were cultured for another 24h-period, adding PTHrP peptides at 100 
nM for the last 30 min. Subsequently, cells were subjected to mechanical stimulation by 
fluid flow with a shear stress of 10 dynes/cm2 in an 8 Hz pulsatile manner for 10 min in 
a Flexcell® Streamer® shear stress device (Flexcell International Corp., Hillsborough, 
NC) (14,25).  
MLO-Y4 cells were transfected with a mixture of two (si)RNA duplexes (each 
at 20 nM) against different target sequences in mouse PTH1R (siPTH1R) (Life 
Technologies, Carlsbad, CA, USA) using Lipofectamine RNAiMax (Life Technologies) 
overnight at 37°C. A si scramble (control siRNA-A; Santa Cruz Biotechnology) was 
used as a negative control. The VEGFR2 antagonist SU5416 (1 mM; Sigma– Aldrich, 
St. Louis, MO) was added 30 min before PTHrP (107-111) addition. 
9 
 
In vitro apoptosis assessment  
After fluid flow, MLO-Y4 were exposed to the pro-apoptotic agent etoposide 
(50 µM) and/or the PTHrP peptides, in the absence of serum for 6 h and subsequently 
fixed with neutral buffer formalin. Apoptosis was assessed by enumerating cells 
expressing nuclear green fluorescent protein (nGFP) exhibiting chromatin condensation 
and nuclear fragmentation under a fluorescence microscope (24). Cell death was 
quantified by Trypan blue uptake of nonadherent cells pooled with adherent cells. The 
percentage of apoptotic cells in the absence of etoposide was 3.6±1.3 %.  
Western blot analysis  
For Bcl-2 western analysis, total protein lysates from MLO-Y4 where obtained 
using RIPA buffer, pH 8.0 (Sigma-Aldrich), supplemented with protease inhibitor 
cocktail P8340 (Sigma–Aldrich) and phosphatase inhibitor cocktail Set II (Calbiochem, 
La Jolla, CA). For β-catenin and ERK western analysis, nuclear protein extracts were 
obtained using the subcellular protein fractionation kit (Pierce, Rockford, IL), according 
to manufacturer’s instructions. Proteins (25-30 μg) were separated by PAGE as 
previoiusly published (25). Blots were probed with rabbit polyclonal anti-Bcl-2 (1:1000, 
Santa Cruz Biotechnology), anti-β-catenin (Abcam, Cambridge, MA), anti-ERK1/2 
(Cell Signaling, Beverly, MA), or anti-lamin B1 (Abcam) antibodies. Mouse 
monoclonal anti-α-tubulin (Sigma Aldrich) or rabbit polyclonal anti-lamin B1 (Abcam) 
antibodies were used as loading control. Subsequently, membranes were incubated with 
the corresponding horseradish peroxidase-coupled anti-rabbit antibodies (Santa Cruz 
Biotechnology); and developed with ECL system (GE-Amersham Pittsburgh, PA). 
Band intensities were quantified by densitometry. 
Statistical analysis   
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Seven-10 mice/condition were used to achieve enough statistical power for the 
detection of >2% changes in bone mass and strength induced by the treatments, based 
on previous studies (16,18,26). Means ± standard deviations (SD) are reported; p<0.05 
were considered significant. Statistical analysis was performed using GraphPad Prism 
(GraphPad Software, La Jolla, CA) and SigmaStat (SPSS Science, Chicago, IL). Data 
were analyzed by one- or two-way ANOVA and, if a significant effect or interaction 
was found, it was further examined by performing pair-wise multiple comparisons with 
Tukey tests. For the loading experiments, differences between loaded and non-loaded 
ulnae were evaluated by paired t-test. For in vitro experiments, data represent 2-3 
experiments carried out in triplicate and analyzed by Kruskal-Wallis test followed by 
Mann-Whitney test.  
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Results 
The skeletal deterioration exhibited by T1D mice is corrected by treatment with 
PTHrP(1-36) or PTHrP(107-111) peptides. 
The experimental design of the in vivo study is shown in Figure 1A. All mice 
were diabetic after 3 weeks following STZ injections, as shown by increased glucose 
concentration in the serum (Figure 1B). Mice remained hyperglycemic until the end of 
the study. The average body weight at the beginning of the study was 26.9 g, ranging 
from 21.7 to 30.3 g; whereas at the end of the study, diabetic mice exhibited decreased 
body weight. Treatment with either PTHrP peptide did not alter glycemia or body 
weight.  
Diabetic mice showed decreased total, spinal, and femoral BMD (t1) by 6-9% 
(Figure 1C and D). A further decrease compared to control non-diabetic mice in spinal 
and femoral BMD of 4.1 and 3.8%, respectively, was observed 15 days later (t2-t1) in 
vehicle-treated diabetic mice compared to control mice, but not in diabetic mice treated 
with either PTHrP peptide (Figure 1E). μCT analysis revealed that cortical bone area 
(BA/TA) and cortical thickness (Ct.Th) were decreased (by 16%) and marrow cavity 
area was increased (by 11%) in the femur mid-diaphysis in diabetic mice; and that all 
parameters were normalized by treatment with the PTHrP peptides (Figure 1F). 
Further, diabetic mice showed a decrease of 50% in cancellous bone (BV/TV) and of 
27% in trabecular thickness (Tb. Th) in the distal femur compared to controls (Figure 
1G). PTHrP(107-111) partially restored BV/TV and both peptides increased trabecular 
thickness compared to untreated diabetic mice.  
The decrease in cancellous bone is accompanied by a decrease of 33-39% in 
osteoblast number (NOb/BS), osteoblast surface (ObS/BS), and osteoid surface 
(OS/BS), and by an increase of 32-63% in osteoclast number (NOc/BS, 49%), 
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osteoclast surface (OcS/BS, 32%), and eroded surface (ES/BS, 63%) in diabetic mice 
(Figure 2A). These changes were reversed by treatment with the PTHrP peptides. On 
the other hand, osteocyte density (NOt/BV) was not affected by any of the treatments. 
Consistent with the changes in osteoblast number, mineralizing surface (MS/BS) and 
mineral apposition rate (MAR) were decreased in vertebral cancellous bone of diabetic 
mice, resulting in a reduction in bone formation rate (BFR/BS) of 49% (Figure 2B). 
Both PTHrP peptides reversed these changes to levels undistinguishable from control 
non-diabetic mice. Bone formation indexes were not significantly reduced on the 
endocortical surface of the ulna in diabetic mice. Nevertheless, both PTHrP peptides 
increased by 61-54% endocortical bone formation compared to control non-diabetic 
mice (Figure 2C).  
 Biomechanical parameters of femoral cortical bone were next evaluated by the 
three point bending test. Diabetic mice exhibited a significant reduction in mean energy 
to failure (51%), ultimate force (43%) and stiffness (32%), compared to control mice 
(Figure 3A). Furthermore, the material properties of bone ultimate stress, toughness, 
and Young’s modulus were also decreased in diabetic mice by 23-43% (Figure 3B). 
Treatment with either PTHrP normalized the altered bone mechanical properties in the 
diabetic mice (Figure 3).  
 
The alterations in bone resorption and formation and in gene expression in bone 
exhibited by T1D mice are corrected by PTHrP peptides.  
 Evaluation of circulating bone remodeling markers at the end of the study 
showed increased CTX (50%) and decreased osteocalcin (62%) in the diabetic mice; 
and these changes were at least partially reversed by PTHrP treatment (Figure 4A). 
Bones from T1D mice exhibited ~80% decreased expression of osterix, which is 
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expressed in a fraction of osteoblast precursors and also highly expressed in osteoblasts 
and osteocytes, and the PTHrP peptides completely reversed this decrease (Figure 4B). 
The expression of the Wnt/β-catenin antagonists Sost and Dkk1 was markedly increased 
in T1D mice by 575 and 380 %; and whereas the peptides did not alter Dkk1 
expression, they significantly decreased Sost expression to levels similar to those of 
control mice. The expression of the cytokine OPG was decreased by ~80 %, and no 
significant changes in RANKL expression were detected, compared to controls, 
resulting in a 53% increase in the RANKL/OPG ratio (Figure 4C). Treatment with 
PTHrP peptides increased OPG and reduced the RANKL/OPG ratio to levels no 
significantly different from control mice. TRAP gene expression was increased by 
155% in T1D mice and the peptides decreased it to values no significantly different than 
control mice. Similar pattern of expression compared to OPG was founds for connexin 
43 (Cx43), another gene regulated by Wnt singnaling (Figure 4C). In contrast, the 
expression of Axin2, BMP4 and cyclin D1, other Wnt target genes, was not affected by 
any treatment (not shown). The levels of PTHrP and PTH1R in vertebra and tibia were 
not altered in diabetic mice treated with vehicle or with the PTHrP peptides (Figure 
4D). 
 
The increased marrow adiposity exhibited by T1D mice is reversed by PTHrP 
peptides.  
 T1D mice also exhibited an increase of approximatedly 600% in the area 
covered by adipocytes in the bone marrow compared to control mice (Figure 5); and 
treatment with the PTHrP peptides reversed adipocyte area corrected per marrow area. 
Similar findings were observed when adipocyte number was quantified (not shown). 
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Moreover, none of the mechanical loading regimens altered marrow adiposity in 
controls or T1D mice treated with vehicle or the PTHrP peptides (not shown).  
 
PTHrP peptides act additively with mechanical loading to increase bone formation 
in diabetic mice and to prevent osteocyte apoptosis in vivo and in vitro.  
 We next evaluated the ability of mechanical stimulation to induce an osteogenic 
response in control and diabetic mice, in combination with treatment of PTHrP peptides 
(Figure 6). Mechanical stimulation at medium and high magnitude increased periosteal 
bone formation in control mice by 166 and 457%, respectively, whereas diabetic mice 
only showed a response to the highest magnitude of strain of 248%. Treatment with the 
each PTHrP peptide increased bone formation in diabetic mice to similar levels than 
mechanical stimulation alone at high magnitude. Moreover, the increase in bone 
formation induced by each PTHrP peptide was higher in ulnae subjected to the high 
magnitude of loading compared to non-loaded ulnae (765-1019% versus 425-515%, 
respectively), demonstrating an additive effect of the treatment and mechanical 
stimulation in T1D mice (Figure 6C).  
Sclerostin protein expression in osteocytes of diabetic mice was similar to that of 
control mice; and it was not altered by treatment with the PTHrP peptides (Figure 7A). 
On the other hand, the % of sclerostin positive osteocytes was reduced by mechanical 
stimulation at medium and high intensities in control mice (by 25 and 49 %, 
respectively), consistent with earlier findings (16,27) (Figure 7A and B). In contrast and 
consistent with the less sensitivity to loading demonstrated on bone formation, the 
highest magnitude of mechanical strain was required to reduce (by 29%) sclerostin 
expression in diabetic mice, with or without treatment with the PTHrP peptides.  
15 
 
Osteocyte apoptosis in diabetic mice was about 30% compared to 20% in control 
mice (Figure 7C). Loading at medium and high magnitude of strain reduced 
significantly osteocyte apoptosis in control mice to about 15% and at the high 
magnitude also reduced apoptosis in diabetic mice from 33% to 25%. Further, peptide 
treatment reduced the elevated prevalence of osteocyte apoptosis of diabetic mice to 
levels indistinguishable from controls. Moreover, the peptides in combination with high 
magnitude mechanical strain further decreased osteocyte apoptosis to values observed in 
loaded ulna of nondiabetic controls.  
Consistent with the increased osteocyte apoptosis found in T1D hyperglycemic 
mice, MLO-Y4 osteocytic cells cultured in high levels of glucose potentiated the effect 
of the pro-apoptotic agent etoposide (Figure 8A). Addition of the PTHrP peptides 
decreased apoptosis induced by etoposide as well as the further increase in apoptosis 
induced by high glucose. In addition, mechanical stimulation provided by fluid flow 
decreased etoposide-induced apoptosis and culture in high glucose containing medium 
hampered the protective effect of mechanical stimulation. Moreover, the pro-apoptotic 
effect of high glucose was counteracted by each PTHrP peptide. We showed earlier that 
the anti-apoptotic effect of PTHrP (1-37) depends on the expression of the PTHR1 (14). 
On the other hand, the anti-apoptotic effect of PTHrP (107-111) was not altered by 
silencing PTH1R but instead was abolished by inhibition of the VEGF receptor with 
SU5416 (Figure 8B). Mechanical stimulation increased the expression of the anti-
apoptotic protein Bcl-2 under normal glucose levels, but not with high glucose (Figure 
8C). Moreover, PTHrP (1-37), but not PTHrP (107-111), increased Bcl-2 in the 
presence of high glucose, under both static conditions and in cultures subjected to fluid 
flow, adding further support to a different mechanism of action of the two PTHrP 
peptides. These findings are consistent with earlier evidence demonstrating that 
16 
 
promotion of cell survival by PTHrP or PTH through the PTH1R in chondrocytes or 
osteoblasts, respectively, is mediated by increased Bcl-2 (28,29). Although high glucose 
did not affect the expression of Bcl-2 in cultures maintained under static conditions, it 
decreased Bcl-2 in cultures subjected to fluid flow. In the presence of high glucose, 
PTHrP (107-111) or fluid flow alone did not increase Bcl-2 levels, but combination of 
the two stimuli did. 
Exposure of osteocytic cells to high glucose prevented the increase induced by 
mechanical stimulation in nuclear accumulation of β-catenin or ERKs, two events 
associated with the pro-survival action of several stimuli in osteocytes (14,25,30,31) (Figure 
8D). However, high glucose did not affect the basal levels of the proteins. In addition, 
the PTHrP peptides induced nuclear accumulation of β-catenin and ERKs in cells 
cultured under normal or high glucose levels.   
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Discussion 
We characterized herein, at the tissue, cellular and molecular levels, the 
mechanisms underlying the bone fragility associated with diabetes and the 
counteracting beneficial effects of two peptides derived from PTHrP, alone or in 
combination with mechanical stimulation, using a mouse model of T1D. Our findings 
demonstrate that diabetes increases bone resorption, decreases bone formation and 
induces apoptosis of osteocytes, resulting in decreased bone mass and deterioration of 
the microarchitecture and the mechanical properties of bone. The PTHrP-derived 
peptides were effective in attenuating the deleterious effects of diabetes; and they 
exhibited additive effects in conjunction with mechanical stimulation. Our findings 
show that diabetes in vivo and high glucose in vitro increased apoptosis of osteocytes; 
and that the PTHrP peptides or mechanical loading attenuate this effect. Moreover, the 
PTHrP peptides promote osteocyte viability by activating similar mechanisms than 
those induced by mechanical stimulation, which involve stabilization of β-catenin, the 
mediator of the canonical Wnt signaling, as well as activation of the ERK survival 
kinases. However, PTHrP (1-37) acts through the PTH1R whereas PTHrP (107-111) 
does not and requires activation of the VEGFR2 receptor. Diabetic mice also exhibited 
high levels of expression of mRNA transcripts for Sost/sclerostin, an antagonist of 
canonical Wnt signaling expressed in osteocytes that potently inhibits bone formation. 
Taken together, these findings strongly suggest a crucial role of osteocytes in the 
harmful effects of diabetes on bone and raise the possibility of targeting osteocytes as a 
novel approach to treat skeletal deterioration in diabetes.  
A higher magnitude of strain was needed to induce periosteal bone accrual and 
to inhibit osteocyte apoptosis after loading in diabetic mice compared to control non-
diabetic mice, demonstrating that diabetic bone is less responsive to mechanical forces. 
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Remarkably, co-treatment with the PTHrP peptides was able to increase the anabolic 
and anti-apoptotic effect on osteocytes induced by loading in vivo. Likewise, the PTHrP 
peptides prevented the impaired response to fluid flow exhibited by osteocytic cells 
cultured in high glucose levels on viability and pro-survival signaling. Moreover, high 
glucose differentially influences the response to fluid flow versus the PTHrP peptides, 
supporting the notion that different mechanisms are activated by the two stimuli 
upstream of Bcl-2, β-catenin, and ERKs. Taking together, these findings suggest a 
crosstalk between mechanical stimuli and PTHrP-activated signaling that additively 
counteracts the damaging actions of diabetes on osteoblast activity and osteocyte 
survival.  
Decreased osteoblast number and function has consistently been reported in the 
STZ-induced diabetic animal models as well as in other insulin-dependent diabetic 
models (4,10,32-36) On the other hand, the role of osteoclasts in this setting is less clear. 
Similar to our findings, bone resorption is increased in short-term diabetes in rats or 
severe diabetes in some, but not all, mouse strains (37,38). However, several studies in 
T1-diabetic rodents show decreased osteoclast activity (37). Moreover, exposure of 
murine pre-osteoclasts to high glucose has been shown to inhibit both 
osteoclastogenesis and osteoclast activity in vitro (39). Thus, differences in disease 
severity, mouse strain, species and even age might contribute to the different bone 
resorption status observed in various studies using diabetic models (40,41).  
Recent studies point to alterations in the Wnt/β-catenin pathway as an important 
mechanism underlying T1D-related bone dysfunction (10,36,42). Two inhibitors of the 
pathway, namely Dkk1 and Sost, were shown to be overexpressed in the long bones of 
diabetic mice. Furthermore, transcripts for both inhibitors were also up-regulated in 
bones from STZ-induced diabetic rats, together with inhibition of Wnt signaling and 
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osteoblastogenesis, associated with insulin deficiency (36). We also found that Sost 
mRNA was increased in bones of diabetic mice. Although we could not detect 
significant changes in the percentage of osteocytes expressing sclerostin in the current 
study, we cannot exclude the possibility that the expression of the protein per osteocyte 
is decreased in diabetic mice. Nevertheless, higher magnitude of load is necessary to 
reduced sclerostin levels in diabetic mice compared to control non-diabetic mice, 
indicating that the mechanisms involved in regulating sclerostin expression are affected 
by diabetes. Moreover, treatment with the PTHrP peptides reversed the up-regulation of 
Sost mRNA expression and induced bone formation in the diabetic mice. Dkk1 was also 
increased in bones from diabetic mice in our study. However, the PTHrP peptides did 
not reverse this increased. The reason for the inability of the PTHrP peptides to decrease 
the upregulated expression of Dkk1 in T1D mice is not known at this time. However, 
earlier studies showed that similar PTHrP peptides decreased Dkk1 expression, which is 
elevated in ovariectomized mice (43). In this previous study, the peptides were 
administered at higher doses than in the current study, for 4 and 8 weeks, and 
throughout the study until samples were collected. In our study, the peptides were given 
only for 3 days, and samples were collected 12 days after the last peptide injection. 
Therefore, it is possible that these differences in the therapeutic regimens combined 
with the different underlying pathology (ovariectomy versus diabetes) explain the 
differential effect of the peptides on Dkk1 expression.  
The rationale for testing the effectiveness of PTHrP peptides in diabetic models 
is based on the pharmacologic ability of the peptides to stimulate bone formation  (44), 
which is decreased with T1D (32). Earlier studies showed that N-terminal PTHrP 
analogue (1-36) and the native C-terminal fragment of PTHrP, PTHrP(107-139), 
different analogs from the ones used here, elicited osteogenic effects in CD1 mouse 
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STZ-diabetic model, albeit at higher doses and after prolonged administration compared 
to the current experiment (4). Our present study represents the first attempt to use an 
experimental maneuver combining short PTHrP treatment with mechanical loading as a 
strategy to promote bone formation in diabetes. Regarding the receptors activated by 
each PTHrP peptide used in our study, the anabolic actions of all peptides comprising 
N-terminal domains of PTHrP tested so far are mediated through the PTH1R in 
osteoblast lineage cells, including osteocytes, and mainly involve cAMP as well as non-
classical PTH1R-dependent signaling pathways such as MAPK activation (5,14). In 
contrast, antagonizing the PTH1R does not alter the action of peptides comprising the 
C-terminal domains of PTHrP, which appear to be related to VEGFR2 transactivation in 
osteoblasts (5,45,46). Consistent with this earlier evidence, we now show that silencing the 
PTH1R in osteocytic MLO-Y4 cells does not eliminate the antiapoptotic effect of 
PTHrP (107-111); and that a VEGFR2 activation inhibitor blocked the effect of PTHrP 
(107-111). These findings demonstrate that the protective effect of the PTHrP peptides 
is mediated by different mechanisms of action. 
An earlier study showed additive, although moderate, efficacy of daily 
administration of PTH(1-34) together with mechanical loading in promoting 
periprosthetic cancellous bone accrual in rabbit femoral metaphysis (47). The fact that 
mechanical or pharmacological stimuli independently decreased or stimulated 
osteoclastogenesis, respectively, might explain the mild effect on bone compared to the 
current study in which ulna loading and the PTHrP-derived peptides were shown to 
additively increase bone. Consistent with the current data, the peptides studied exhibited 
bone anabolic activity in mouse and rat cortical bone (44,48,49). 
We recently reported that N-terminal PTHrP is similarly effective as mechanical 
loading to protect MLO-Y4 osteocytic cells from apoptosis (14). Deleterious effects of 
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high glucose on various responses of this osteocytic cell line to fluid flow stimulation 
were also recently reported (8). Our in vitro data show that PTHrP(1-37) and (107-111) 
were similarly effective to increase MLO-Y4 cell viability even in the presence of high 
glucose. Moreover, the impaired response to fluid flow-mechanical stimulus in the latter 
setting was also prevented by the peptides. Further, both the PTHrP peptides and fluid 
flow activated ERKs and induced β-catenin nuclear translocation. These findings are 
consistent with our previous evidence that N- and C-terminal domains of PTHrP enable 
β-catenin stabilization, which is hampered by high glucose, in osteoblastic cell cultures 
(42). 
In summary, our findings collectively demonstrate that bone fragility induced by 
diabetes is due to a combination of increased bone resorption, decreased bone formation 
and decreased viability of osteocytes. Further, short treatment with the PTHrP-derived 
peptides ameliorates these effects and acts additively with mechanical stimulation to 
prevent bone fragility induced by diabetes (Figure 9). This evidence highlights the 
potential of approaches that control bone remodeling and maintain viability and 
function of osteocytes in the treatment of diabetes-induced skeletal deterioration.  
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Figure legends  
Figure 1. T1D mice exhibit decreased BMD and weakened bone microarchitecture 
that is corrected by PTHrP-derived peptides. (A) Experimental scheme showing the 
animal model protocol, indicating the point in which the experiment started (t0), when 
mechanical loading/peptide administration started (t1) and the time of sacrifice (t2). (B) 
Glucose levels and body weight measured in blood from mice at t2. (C) Total, spine and 
femur BMD at t1. (D) Percent change in spine and femur BMD from t0 to t1. (E) 
Percent change in spine and femur BMD from t1 to t2. n= 28-30 per group. (F and G) 
Analysis and representative images of bone microarchitecture by μCT in cortical 
(femoral mid-diaphysis) and cancellous (distal femur). n= 7-10 per group. Scale bars 
indicate 500 μm. Bars represent mean ± SD,*p<0.05 versus control mice, #p<0.05 
versus T1D, by one-way ANOVA. 
Figure 2. T1D mice exhibit decreased osteoblasts and bone formation and 
increased osteoclasts and these effects are reversed by PTHrP-derived peptides. 
(A) Osteoblasts, osteoclasts and osteocytes were identified in mice bone sections from 
lumbar vertebrae stained by von Kossa/McNeal. Number of osteoblasts per bone surface 
(NOb/BS), surface covered by osteoblasts (ObS/BS), osteoclast number per bone 
surface (NOc/BS), surface covered by osteoclasts (OcS/BS), eroded surface per bone 
surface (ES/BS) and osteocyte number per bone volume (NOt/BV), were reported. Bars 
represent mean ± SD, n= 7-10 per group. Dynamic bone histomorphometric analysis 
was performed in (B) the cancellous surface of lumbar vertebrae and (C) endocortical 
surface of the ulna mid-diaphysis. Mineralizing surface (MS/BS), mineral apposition 
rate (MAR) and bone formation rate (BFR) were measured in unstained sections. (B) n= 
6-10 per group, (C) n= 19-24 per group. Bars represent mean ± SD, *p<0.05 versus 
control mice, #p<0.05 versus vehicle-treated T1D mice, by one-way ANOVA. 
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Representative images of von Kossa/McNeal stained (A) and fluorescent images (B) of 
bone sections are shown. White arrows point at osteoblasts (ob), osteoclasts (oc) or 
osteoid (os). Scale bars indicate 500 μm.  
Figure 3. T1D mice exhibited defective mechanical and material properties, which 
are restored by treatment with PTHrP-derived peptides. (A) Mechanical and (B) 
material properties were measured in the femoral mid-diaphysis by 3-point bending 
testing. n= 7-10 per group. Bars represent mean ± SD, * p<0.05 versus control mice, # 
p<0.05 versus vehicle-treated T1D mice, by one-way ANOVA. 
Figure 4. PTHrP-derived peptides counteract the changes in bone resorption and 
formation markers and in bone gene expression induced by T1D. (A) C-telopeptide 
fragments of type I collagen (CTX) and osteocalcin (OCN) measured at the end of the 
study in serum and plasma, respectively. (B-D) Expression of the the osteoblast marker 
osterix, and the Wnt/β-catenin antagonists, dkk1 and Sost, cytokines OPG and RANKL 
and the RANKL/OPG ratio, the osteoclast marker TRAP, Cx43, PTHrP and PTHR1 in 
tibia. n= 7-10 per group. Bars represent mean ± SD, * p<0.05 versus control mice, # 
p<0.05 versus vehicle-treated T1D mice, by one-way ANOVA. 
Figure 5. T1D mice exhibit increased marrow adiposity, which is reduced by the 
PTHrP peptides. (A) Areas covered by adipocytes were measured in ulnae mid-
diaphysis and corrected by marrow area. n= 5-6 mice per group. Bars represent mean ± 
SD, * p<0.05 versus non diabetic control mice and # p<0.05 versus T1D mice, by one-
way ANOVA. (B) Representative images are shown. Scale bar indicates 25 μm. 
Figure 6. T1D mice exhibit decreased sensitivity to loading, which is restored by 
PTHrP-derived peptides alone and additively with mechanical stimulation. Bone 
histomorphometric measurements were performed on non-loaded and loaded ulnae at 
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(A) low (1,995 µε), (B) medium (2,250 µε), and (C) high (2,500 µε) magnitudes of 
strain. n= 5-8 per group. Bars represent mean ± SD, * p<0.05 versus the corresponding 
non-loaded mice by paired t-test. # p<0.05 versus loaded saline mice, a p<0.05 versus 
corresponding (loaded or non-loaded) vehicle-treated T1D mice, by two-way ANOVA. 
Representative fluorescent images corresponding to the highest intensity are shown. 
Scale bar indicates 500 μm. 
Figure 7. Loading decreases sclerostin and both loading and the PTHrP peptides 
reverse T1D-induced osteocyte apoptosis in vivo. Osteocytes from non-loaded and 
loaded ulnae cross sections at low, medium, and high magnitude of strain were stained 
and scored for (A) and (B) sclerostin and (C) TUNEL, to determine apoptosis. n= 5-8 
per group. Bars represent mean ± SD, *p<0.05 versus the corresponding non-loaded 
mice by paired t-test. #p<0.05 versus loaded saline mice, ap<0.05 versus corresponding 
(either loaded or non-loaded) T1D vehicle-treated mice, by two-way ANOVA.  
Figure 8. Mechanical stimulation and PTHrP peptides elicit pro-survival signals in 
vitro (A) MLO-Y4 osteocytic cells expressing nGFP exposed to normal glucose or high 
glucose (25 mM) and with or without PTHrP-derived peptides were subjected to fluid 
flow or static control conditions and apoptosis was quantified by nuclear morphology.  
PTHrP did not change the number of living cells. (B) MLO-Y4 cells silenced for 
PTH1R or treated with scramble siRNA were treated with the specific VEGFR2 
inhibitor SU5416 for 30 min and subsequently with PTHrP (107-111) for additional 30 
min. Cell viability was measured after etoposide addition, as described in Materials and 
Methods. Bars represent mean ± SD of 3 experiments carried out in duplicate, *p<0.05 
versus corresponding vehicle-treated cells, by one-way ANOVA followed by Tukey 
test. (C and D) Bcl-2, β-catenin, and ERK nuclear protein levels were quantified by 
Western blotting. The dividing lines in the β-catenin and lamin B1 western blot indicate 
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different parts of the same gel. Bars represent mean ± SD of 2-3 experiments carried out 
in duplicate (Bcl-2) or triplicate (β-catenin and ERKs), *p<0.05 versus normal glucose, 
static control; #p<0.05 versus high glucose, static control; ap<0.05 versus high glucose, 
fluid flow, by Kruskal-Wallis test followed by Mann-Whitney test. 
Figure 9. Working model. PTHrP(1-37) or PTHrP(107-111) reversed the skeletal 
deterioration in T1D, partially restoring the loss of bone mass and strength, and 
reversing the decreased bone formation and increased Sost expression and resorption. 
Furthermore, the PTHrP peptides worked additively with mechanical loading to 
enhance periosteal bone formation and reduce osteocytic apoptosis in the appendicular 
skeleton of diabetic mice.  
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